Publications

Peer-reviewed science behind our pipeline.

Selected publications from the ScarTec team and collaborators across fibrosis, oncology, integrin biology, and peptide therapeutics.

Showing 5 of 5 publications

Acta Pharmaceutica Sinica B2026

Engineered cyclic peptide targeting ITGA5 disrupts tumor-stroma interaction to overcome desmoplasia and resistance in pancreatic ductal adenocarcinoma

Prakash J, Metselaar JM, et al.

An engineered cyclic peptide (cyAV3.3) targeting integrin α5 disrupts CAF-driven desmoplasia and tumor–stroma crosstalk, reducing resistance and stemness markers, decompressing tumor vasculature, and potentiating gemcitabine efficacy in xenograft and KPC PDAC models.

OncologyIntegrinsPeptide therapeuticsFibrosis
Read publication
Science Advances2019

ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer

Kuninty PR, Bansal R, De Geus SWL, Mardhian DF, Schnittert J, van Baarlen J, Storm G, Bijlsma MF, van Laarhoven HW, Metselaar JM, Kuppen PJK, Vahrmeijer AL, Ostman A, Sier CFM, Prakash J.

Selective inhibition of integrin α5 (ITGA5) on pancreatic stellate cells reduces desmoplasia and restores the efficacy of chemotherapy in preclinical models of pancreatic ductal adenocarcinoma.

OncologyIntegrinsFibrosis
Read publication
Trends in Cancer2019

Targeting pancreatic stellate cells in cancer

Schnittert J, Bansal R, Prakash J.

A review of therapeutic strategies targeting activated pancreatic stellate cells to remodel the tumor stroma and improve treatment outcomes in pancreatic cancer.

OncologyFibrosis
Read publication
FASEB Journal2019

Integrin α11 in pancreatic stellate cells regulates tumor stroma interaction in pancreatic cancer

Schnittert J, Bansal R, van Baarlen J, Ostman A, Prakash J.

Integrin α11 on pancreatic stellate cells mediates tumor–stroma crosstalk, supporting its role as a therapeutic target in the desmoplastic microenvironment of pancreatic cancer.

OncologyIntegrinsFibrosis
Read publication
Experimental & Molecular Medicine2017

Integrin alpha 11 in the regulation of the myofibroblast phenotype: implications for fibrotic diseases

Bansal R, Nakagawa S, Yazdani S, van Baarlen J, Venkatesh A, Koh AP, Song W, Goossens N, Watanabe H, Beasley MB, Powell CA, Storm G, Kaminski N, van Goor H, Friedman SL, Hoshida Y, Prakash J.

Integrin α11 is identified as a key regulator of the myofibroblast phenotype across fibrotic tissues, supporting its therapeutic relevance in liver, lung, and other fibrotic diseases.

FibrosisIntegrins
Read publication